DeepMed Research

Fenofibrate

Generic Name: Fenofibrate

Brand Names: Antara, Cholib, Fenoglide, Fenomax, Lipidil Supra, Lipofen, Tricor, Triglide

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁ClO_₄

CAS Number: 49562-28-9

Unique Ingredient Identifier: U202363UOS

Background: Fenofibrate is a fibric acid derivative like clofibrate and gemfibrozil. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.

Fenofibrate was granted FDA approval on 31 December 1993.

Indication: Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.

Associated Conditions: Mixed Dyslipidemias, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Severe Fredrickson Type IV Hypertriglyceridemia, Severe Fredrickson Type V Hypertriglyceridemia

Clinical Trials

Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation

Phase 2

Recruiting

Conditions: Primary Sclerosing Cholangitis
Liver Transplant, Complications
PSC
Biliary Strictures

Interventions: Drug: Fenofibrate (drug)
Diagnostic Test: Blood draw for the laboratory assessment
Diagnostic Test: MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)

First Posted Date: 2025-04-01

Last Posted Date: 2025-04-17

Lead Sponsor: Mayo Clinic

Target Recruit Count: 80

Registration Number: NCT06905054

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States

Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia

Not yet recruiting

Conditions: Atherosclerotic Cardiovascular Disease

Interventions: Drug: Atorvastatin
Drug: Simvastatin
Drug: Rozuvastatin
Drug: Ezetimibe
Drug: Niacin
Drug: Ciprofibrate
Drug: Fenofibrate
Drug: Bezafibrate
Drug: Evolocumab
Drug: Alirocumab
Drug: Inclisiran

First Posted Date: 2025-03-05

Last Posted Date: 2025-03-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2382

Registration Number: NCT06858332

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

Phase 3

Recruiting

Conditions: Primary Biliary Cholangitis (PBC)

Interventions: Drug: Fenofibrate in Combination With Ursodeoxycholic Acid

First Posted Date: 2025-01-01

Last Posted Date: 2025-01-01

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 150

Registration Number: NCT06755541

Locations: 🇨🇳
Xijing hospital, Xi'an, Shaanxi, China

Fenofibrate in Primary Biliary Cholangitis: a Real World Study

Phase 3

Recruiting

Conditions: Primary Biliary Cholangitis (PBC)

Interventions: Drug: Fenofibrate

First Posted Date: 2025-01-01

Last Posted Date: 2025-01-01

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 300

Registration Number: NCT06755151

Locations: 🇨🇳
Xijing hospital, Xi'an, Shaanxi, China

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

Phase 2

Active, not recruiting

Conditions: Non Alcoholic Fatty Liver Disease

Interventions: Drug: Pemafibrate low dose
Drug: Fenofibrate
Drug: Pemafibrate high dose

First Posted Date: 2024-10-02

Last Posted Date: 2024-10-02

Lead Sponsor: Yokohama City University

Target Recruit Count: 360

Registration Number: NCT06623539

Locations: 🇯🇵
Yokohama city university, Yokohama, Kanagawa, Japan

A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis

Early Phase 1

Conditions: Primary Biliary Cholangitis (PBC)

Interventions: Drug: Fenofibrate
Drug: UDCA (Ursodeoxycholic acid)

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-27

Lead Sponsor: Han Ying

Target Recruit Count: 30

Registration Number: NCT06591455

Locations: 🇨🇳
Xijing hospital, Xi'an, Shaanxi, China

Role of Fenofibrate in Neonatal Jaundice

Phase 4

Completed

Conditions: Neonatal Jaundice

Interventions: Other: placebo
Drug: Fenofibrate

First Posted Date: 2024-06-11

Last Posted Date: 2024-06-11

Lead Sponsor: Ain Shams University

Target Recruit Count: 75

Registration Number: NCT06451900

Locations: 🇪🇬
Ain Shams University Hospitals, Cairo, Abbassia, Egypt

Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)

Phase 2

Recruiting

Conditions: Primary Biliary Cholangitis

Interventions: Drug: Fenofibrate
Drug: UDCA

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: Xijing Hospital of Digestive Diseases

Target Recruit Count: 117

Registration Number: NCT06365424

Locations: 🇨🇳
Xijing Hospital, Xi'an, Shaanxi, China

Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice.

Phase 2

Not yet recruiting

Conditions: Physiological Neonatal Jaundice
Physiological Hyperbilirubinaemia

Interventions: Device: Phototherapy
Drug: Fenofibrate

First Posted Date: 2024-04-04

Last Posted Date: 2024-04-04

Lead Sponsor: Muhammad Zark

Target Recruit Count: 156

Registration Number: NCT06346743

Locations: 🇵🇰
Services Institute of Medical Sciences, Lahore, Punjab, Pakistan

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Phase 1

Recruiting

Conditions: Invasive Cervical Cancer
Cervical Intraepithelial Neoplasia

Interventions: Drug: Fenofibrate
Procedure: Hysterectomy
Procedure: Cervical Conization
Radiation: Chemoradiation

First Posted Date: 2024-01-05

Last Posted Date: 2025-04-11

Lead Sponsor: Lindsay Ferguson, MD

Target Recruit Count: 24

Registration Number: NCT06191133

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy